Brice Chanez

Marseille, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 46 publications

Neoadjuvant immunotherapy followed by surgery versus non-operative management in dMMR/MSI gastroesophageal adenocarcinomas: a case series and review of the literature.

Neoadjuvant immunotherapy followed by surgery versus non-operative management in dMMR/MSI gastroesophageal adenocarcinomas: a case series and review of the literature.

Journal: ESMO gastrointestinal oncology
Published: August 12, 2026

Pathway-driven therapeutic stratification in pancreatic ductal adenocarcinoma.

Pathway-driven therapeutic stratification in pancreatic ductal adenocarcinoma.

Journal: Translational oncology
Published: May 11, 2026

Randomized, multicenter Phase III trial of adjuvant chemotherapy with modified FOLFIRINOX versus capecitabine or gemcitabine in patients with resected ampullary adenocarcinoma.

Randomized, multicenter Phase III trial of adjuvant chemotherapy with modified FOLFIRINOX versus capecitabine or gemcitabine in patients with resected ampullary adenocarcinoma.

Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
Published: December 31, 2025

Adjuvant capecitabine in resected biliary tract cancer: a real-world data from the BILCAP-Real study (ACABi multicentre cohort).

Adjuvant capecitabine in resected biliary tract cancer: a real-world data from the BILCAP-Real study (ACABi multicentre cohort).

Journal: JHEP reports : innovation in hepatology
Published: December 18, 2025

Factors Associated With Toxicity of FOLFIRINOX in Elderly Patients With Pancreatic Ductal Adenocarcinoma.

Factors Associated With Toxicity of FOLFIRINOX in Elderly Patients With Pancreatic Ductal Adenocarcinoma.

Journal: JCO oncology practice
Published: December 15, 2025

Hyperprogression after Immune Checkpoint Inhibitors: A Cloudy Phenomenon with Real-life Consequences.

Hyperprogression after Immune Checkpoint Inhibitors: A Cloudy Phenomenon with Real-life Consequences.

Journal: Cancer communications (London, England)
Published: November 23, 2025

Stage-resolved gene drivers of pancreatic ductal adenocarcinoma progression and therapeutic vulnerabilities.

Stage-resolved gene drivers of pancreatic ductal adenocarcinoma progression and therapeutic vulnerabilities.

Journal: iScience
Published: September 24, 2025

A comprehensive proteomic dataset of secretomes from primary pancreatic cancer cell cultures.

A comprehensive proteomic dataset of secretomes from primary pancreatic cancer cell cultures.

Journal: Scientific data
Published: September 18, 2025

Toward Precision Chemotherapy for Pancreatic Cancer Guided by Transcriptomic Signatures.

Toward Precision Chemotherapy for Pancreatic Cancer Guided by Transcriptomic Signatures.

Journal: United European gastroenterology journal
Published: August 17, 2025

Single-cell transcriptomic profiling of patient-derived pancreatic ductal adenocarcinoma primary cell cultures.

Single-cell transcriptomic profiling of patient-derived pancreatic ductal adenocarcinoma primary cell cultures.

Journal: Scientific data
Published: July 31, 2025

Medical management of pancreatic cancer: from personalization to broadening treatment strategies.

Medical management of pancreatic cancer: from personalization to broadening treatment strategies.

Journal: Cancer treatment reviews
Published: May 14, 2025

Real-world efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient biliary tract cancer: An AGEO study.

Real-world efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient biliary tract cancer: An AGEO study.

Journal: European journal of cancer (Oxford, England : 1990)
Published: April 01, 2025
Showing 1-12 of 46

Last Updated: 09/26/2026